DNDi ’s VISION
To improve the quality of life and the health of people suffering from neglected diseases by using an alternative model to develop drugs for these diseases, and by ensuring equitable access to new and field-relevant health tools. In this not-for-profit model, driven by the public sector, a variety of players collaborate to raise awareness of the need to research and develop drugs for those neglected diseases that fall outside the scope of market-driven research and development (R&D). They also build public responsibility and leadership in addressing the needs of these patients.
R&D partners worldwide
DNDi ’s MISSION
• To develop new drugs or new formulations of existing drugs for people living with neglected diseases. Acting in the public interest, DNDi bridges existing R&D gaps in essential drugs for these diseases by initiating and coordinating drug R&D projects in collaboration with the international research community, the public sector, the pharmaceutical industry, and other relevant partners. • DNDi’s primary focus has been the development of drugs for the most neglected diseases, such as human African trypanosomiasis (HAT, or sleeping sickness), leishmaniasis, and Chagas disease, while considering engagement in R&D projects for other neglected patients (e.g. malaria, paediatric HIV, filarial infections) and development of diagnostics and/or vaccines to address unmet needs that others are unable or unwilling to address. • In pursuing these goals, DNDi enables R&D networks built on global collaborations. While harnessing existing support capacities in countries where the diseases are endemic, DNDi contributes to strengthening capacities in a sustainable manner, including through knowhow and technology transfers in the field of drug R&D for neglected diseases. • In order to address evolving needs of public health importance and maintain DNDi’s commitment to delivering on the objectives of the current portfolio of diseases, a dynamic portfolio approach has been adopted. This enables DNDi to take on new disease areas with various operating models, while completing objectives in current diseases.
new treatments delivered
clinical research platforms established